相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drugging undruggable genes for cancer treatment: Are we making progress?
Michael J. Duffy et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases
Ewelina Kulikowski et al.
MEDICINAL RESEARCH REVIEWS (2021)
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire M. Patterson et al.
COMMUNICATIONS BIOLOGY (2021)
BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia
Haley E. Ramsey et al.
CLINICAL CANCER RESEARCH (2021)
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study
Daniel A. Pollyea et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
Clare M. Adams et al.
LEUKEMIA (2020)
Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA
Aaron J. Miller et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
Giovanna Carra et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Emily J. Faivre et al.
NATURE (2020)
Target gene-independent functions of MYC oncoproteins
Apoorva Baluapuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Nicole M. Sodir et al.
CANCER DISCOVERY (2020)
Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma
Hsin-Yi Tseng et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Daniel Masso-Valles et al.
CELLS (2020)
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
Nabanita Mukherjee et al.
CANCERS (2020)
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
Thomas E. C. Cummin et al.
BLOOD ADVANCES (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B. Balachander et al.
CLINICAL CANCER RESEARCH (2020)
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Nabanita Mukherjee et al.
CELL DEATH & DISEASE (2020)
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Surein Arulananda et al.
CELL DEATH DISCOVERY (2020)
被撤回的出版物: Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma (Retracted article. See vol. 15, 2023)
Wenlong Feng et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Marie-Eve Beaulieu et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F. Lee et al.
CELL DEATH & DISEASE (2019)
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Weiping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
Mark J. Demma et al.
MOLECULAR AND CELLULAR BIOLOGY (2019)
BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML
Susu Zhang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2019)
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
Ali Alqahtani et al.
FUTURE SCIENCE OA (2019)
Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
Clare E. Weeden et al.
ONCOGENE (2018)
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
A. Esteve-Arenys et al.
ONCOGENE (2018)
BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
Sa Rang Kim et al.
Oncotarget (2018)
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
Ryan S. Soderquist et al.
NATURE COMMUNICATIONS (2018)
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel et al.
CANCER DISCOVERY (2018)
Exploiting MCL1 Dependency with Combination MEK+MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer
Varuna Nangia et al.
CANCER DISCOVERY (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?
Brandon J. Aubrey et al.
CELL DEATH AND DIFFERENTIATION (2018)
OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors
L. A. Jung et al.
ONCOGENE (2017)
BCL-W has a fundamental role in B cell survival and lymphomagenesis
Clare M. Adams et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour et al.
LANCET ONCOLOGY (2017)
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
S. Peirs et al.
LEUKEMIA (2017)
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
Lloyd T. Lam et al.
MOLECULAR CANCER THERAPEUTICS (2017)
BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
Chiaki Tsuge Ishida et al.
ONCOTARGET (2017)
JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
Huogang Wang et al.
ONCOTARGET (2017)
MYC Deregulation in Primary Human Cancers
Manpreet Kalkat et al.
GENES (2017)
Strategies to Inhibit Myc and Their Clinical Applicability
Jonathan R. Whitfield et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW
Clare M. Adams et al.
CLINICAL CANCER RESEARCH (2017)
The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression
Zhenqian Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
D. Merino et al.
ONCOGENE (2016)
Modified gold nanoparticles for intracellular delivery of anti-liver cancer siRNA
Hanan Shaat et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells
Z. Xu et al.
LEUKEMIA (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Design and characterization of bivalent BET inhibitors
Minoru Tanaka et al.
NATURE CHEMICAL BIOLOGY (2016)
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms
Xiarong Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Bcl-xL is an oncogenic driver in colorectal cancer
Anna-Lena Scherr et al.
CELL DEATH & DISEASE (2016)
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells
Liz J. Valente et al.
CELL REPORTS (2016)
The Quest for Targets executing MYC-Dependent Cell Transformation
Markus Hartl
FRONTIERS IN ONCOLOGY (2016)
MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system
Gustavo Tapia et al.
APMIS (2015)
Role of the pro-survival molecule Bfl-1 in melanoma
C. K. Hind et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2015)
Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer
Haichao Zhang et al.
MOLECULAR CANCER (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
Joel D. Leverson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies
E. Lasorsa et al.
CELL DEATH & DISEASE (2015)
Genome-wide analysis of p53 transcriptional programs in B cells upon exposure to genotoxic stress in vivo
Claudia Tonelli et al.
ONCOTARGET (2015)
MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1
Xiao-nan Chen et al.
CANCER CELL INTERNATIONAL (2014)
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Gemma L. Kelly et al.
GENES & DEVELOPMENT (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
Daniela Annibali et al.
NATURE COMMUNICATIONS (2014)
BIM Is the Primary Mediator of MYC-Induced Apoptosis in Multiple Solid Tissues
Nathiya Muthalagu et al.
CELL REPORTS (2014)
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Meital Gabay et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Sequence specificity incompletely defines the genome-wide occupancy of Myc
Jiannan Guo et al.
GENOME BIOLOGY (2014)
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy
Yuan Zhang et al.
BIOMATERIALS (2013)
In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models
Joao Conde et al.
BIOMATERIALS (2013)
Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model
Qiqi Zhu et al.
CANCER CELL INTERNATIONAL (2013)
Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses
Daniela Kenzelmann Broz et al.
GENES & DEVELOPMENT (2013)
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Laura Soucek et al.
GENES & DEVELOPMENT (2013)
Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
Olivier Mirguet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
MYC-y mice: From tumour initiation to therapeutic targeting of endogenous MYC
Jennifer P. Morton et al.
MOLECULAR ONCOLOGY (2013)
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene et al.
NATURE CHEMICAL BIOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Rizwan Haq et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sandrine Sander et al.
CANCER CELL (2012)
c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Zuqin Nie et al.
CELL (2012)
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Charles Y. Lin et al.
CELL (2012)
Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737
Keryn M. Lucas et al.
CLINICAL CANCER RESEARCH (2012)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
Distinct Regulatory Mechanisms and Functions for p53-Activated and p53-Repressed DNA Damage Response Genes in Embryonic Stem Cells
Mangmang Li et al.
MOLECULAR CELL (2012)
Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
Daniela Senft et al.
PLOS ONE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice
Priscilla N. Kelly et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
Mauro Savino et al.
PLOS ONE (2011)
Deep Sequencing of MYC DNA-Binding Sites in Burkitt Lymphoma
Volkhard Seitz et al.
PLOS ONE (2011)
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
Jose A. Richter-Larrea et al.
BLOOD (2010)
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma
M. E. Gatt et al.
BLOOD (2010)
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim
Lina Happo et al.
BLOOD (2010)
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson et al.
BRITISH JOURNAL OF CANCER (2010)
The ups and downs of Myc biology
Laura Soucek et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
W. J. Placzek et al.
CELL DEATH & DISEASE (2010)
High-Resolution Structural Characterization of a Helical alpha/beta-Peptide Foldamer Bound to the Anti-Apoptotic Protein Bcl-x(L)
Erinna F. Lee et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer
Melissa Crawford et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts
Joslyn K. Brunelle et al.
JOURNAL OF CELL BIOLOGY (2009)
Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma
Athanasios C. Tsiatis et al.
MODERN PATHOLOGY (2009)
MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family
L. J. Beverly et al.
ONCOGENE (2009)
BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma
Masumichi Saito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
Grace M. Callagy et al.
BMC CANCER (2008)
Distinct Thresholds Govern Myc's Biological Output In Vivo
Daniel J. Murphy et al.
CANCER CELL (2008)
Modeling genomic diversity and tumor dependency in malignant melanoma
William M. Lin et al.
CANCER RESEARCH (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute
E. M. Michalak et al.
CELL DEATH AND DIFFERENTIATION (2008)
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models
Alex R. Shoemaker et al.
CLINICAL CANCER RESEARCH (2008)
Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1
Catherine L. Day et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Modelling Myc inhibition as a cancer therapy
Laura Soucek et al.
NATURE (2008)
Recurrent chromosomal abnormalities in human embryonic stem cells
Claudia Spits et al.
NATURE BIOTECHNOLOGY (2008)
Human embryonic stem cells reveal recurrent genomic instability at 20q11.21
Nathalie Lefort et al.
NATURE BIOTECHNOLOGY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Global Identification of Myc Target Genes Reveals Its Direct Role in Mitochondrial Biogenesis and Its E-Box Usage In Vivo
Jonghwan Kim et al.
PLOS ONE (2008)
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1
Jidong Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural plasticity underpins promiscuous binding of the prosurvival protein a1
Callum Smits et al.
STRUCTURE (2008)
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir et al.
NATURE (2007)
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer
Jude Kendall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
mir-29 regulates Mcl-1 protein expression and apoptosis
J. L. Mott et al.
ONCOGENE (2007)
Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
A. Olsson et al.
BRITISH JOURNAL OF CANCER (2007)
Improved low molecular weight Myc-Max inhibitors
Huabo Wang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Endogenous bcl-2 is not required for the development of Eμ-myc-induced B-cell lymphoma
Priscilla N. Kelly et al.
BLOOD (2007)
Structural insights into the degradation of Mcl-1 induced by BH3 domains
Peter E. Czabotar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Myc deletion rescues Apc deficiency in the small intestine
Owen J. Sansom et al.
NATURE (2007)
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
Syed-Rehan A. Hussain et al.
CLINICAL CANCER RESEARCH (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa
Edwina Naik et al.
JOURNAL OF CELL BIOLOGY (2007)
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak
Simon N. Willis et al.
SCIENCE (2007)
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
Cinta Mestre-Escorihuela et al.
BLOOD (2007)
Global mapping of c-Myc binding sites and target gene networks in human B cells
Karen I. Zeller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome
Laura T. Smith et al.
GENES CHROMOSOMES & CANCER (2006)
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma
Andrew P. Weng et al.
GENES & DEVELOPMENT (2006)
Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues
E. Bandres et al.
MOLECULAR CANCER (2006)
A credit-card library approach for disrupting protein-protein interactions
Y Xu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
J Iqbal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
GA Calin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
miR-15 and miR-16 induce apoptosis by targeting BCL2
A Cimmino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
F Feuerhake et al.
BLOOD (2005)
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
MT Hemann et al.
NATURE (2005)
Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas
JI Martín-Subero et al.
GENES CHROMOSOMES & CANCER (2005)
High-resolution genomic profiles of human lung cancer
G Tonon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells
S Kobayashi et al.
GASTROENTEROLOGY (2005)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
GR Devi et al.
CLINICAL CANCER RESEARCH (2005)
Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node
S Mukhopadhyay et al.
HUMAN PATHOLOGY (2005)
Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas
S Knezevich et al.
LEUKEMIA (2005)
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
C Grandori et al.
NATURE CELL BIOLOGY (2005)
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia
AA Morales et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Genome-wide array-based CGH for mantle cell lymphoma:: identification of homozygous deletions of the proapoptotic gene BIM
H Tagawa et al.
ONCOGENE (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Bim is a suppressor of Myc-induced mouse B cell leukemia
A Egle et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
eIF-4E expression and its role in malignancies and metastases
A De Benedetti et al.
ONCOGENE (2004)
Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies
M Linden et al.
BLOOD (2004)
Structural biology of the Bcl-2 family of proteins
AM Petros et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2004)
Antiapoptotic BCL-2 is required for maintenance of a model leukemia
A Letai et al.
CANCER CELL (2004)
MCL-1 expression in B-cell non-Hodgkin's lymphomas
JH Cho-Vega et al.
HUMAN PATHOLOGY (2004)
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation
M Welcker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer
RS Herbst et al.
CLINICAL CANCER RESEARCH (2004)
Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc
PJ Swanson et al.
JOURNAL OF IMMUNOLOGY (2004)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
S Le Gouill et al.
BLOOD (2004)
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice
WC Cheung et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Multiple cell-type-specific elements regulate Myc protein stability
A Herbst et al.
ONCOGENE (2004)
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
D Ruggero et al.
NATURE MEDICINE (2004)
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa
A Villunger et al.
SCIENCE (2003)
c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL
KH Maclean et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Low molecular weight inhibitors of Myc-Max interaction and function
XY Yin et al.
ONCOGENE (2003)
Integral role of Noxa in p53-mediated apoptotic response
T Shibue et al.
GENES & DEVELOPMENT (2003)
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells
ZR Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Skp2 regulates Myc protein stability and activity
SY Kim et al.
MOLECULAR CELL (2003)
Genomic targets of the human c-Myc protein
PC Fernandez et al.
GENES & DEVELOPMENT (2003)
Bfl-1 gene expression in breast cancer: Its relationship with other prognostic factors
HS Yoon et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2003)
Abnormal expression of apoptosis-related genes in haematological malignancies:: overexpression of MYC is poor prognostic sign in mantle cell lymphoma
B Nagy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
X-ray structures of Myc-Max and Mad-Max recognizing DNA: Molecular bases of regulation by proto-oncogenic transcription factors
SK Nair et al.
CELL (2003)
Direct activation of RNA polymerase III transcription by c-Myc
N Gomez-Roman et al.
NATURE (2003)
Predictive value of p53, Bcl-2, and Bax in advanced head and neck carcinoma
S Casado et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1
IM Pedersen et al.
BLOOD (2002)
Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: Study of 116 cases
B Agarwal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes
A Menssen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts
T Berg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes
EC Thornborrow et al.
ONCOGENE (2002)
Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis
CM Eischen et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1
CM Eischen et al.
ONCOGENE (2001)
Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys
MS Webb et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2001)
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
R Sears et al.
GENES & DEVELOPMENT (2000)
The c-myc transactivation domain is a direct modulator of apoptotic versus proliferative signals
DW Chang et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL
M Horita et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells
MA Gregory et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
